CAT Phase I/IIa data

Cambridge Antibody (LSE:CAT) reported results from a U.K. study of its CAT-152 antibody to prevent post-operative scarring in patients undergoing glaucoma surgery. In the 24-patient trial, 11 of 16 tr...